The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis

Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALT...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2025-01, Vol.15, p.1509987
Main Authors: Puthenparampil, Marco, Gaggiola, Marta, Rinaldi, Francesca, Nosadini, M, Sartori, S, Perini, Paola, Gallo, Paolo
Format: Article
Language:English
Subjects:
Age of Onset
alemtuzumab
Alemtuzumab - adverse effects
Alemtuzumab - therapeutic use
Child
Humans
Immunology
induction therapy
multiple sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
pediatric-onset MS
POMS
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published. In this review we have briefly revised the immunopathogenic features of POMS, as well as on how ALTZ might impact on them, reporting its efficacy observed in different POMS cohorts.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1509987